These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35041812)

  • 1. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.
    Hasan Alshammari A; Masuo Y; Fujita KI; Shimada K; Iida N; Wakayama T; Kato Y
    Biochem Pharmacol; 2022 Mar; 197():114914. PubMed ID: 35041812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide.
    Luo P; Yan H; Chen X; Zhang Y; Zhao Z; Cao J; Zhu Y; Du J; Xu Z; Zhang X; Zeng S; Yang B; Ma S; He Q
    Cell Res; 2020 Sep; 30(9):779-793. PubMed ID: 32296111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E
    Shichiri H; Yamamoto K; Tokura M; Ishida T; Uda A; Bito T; Nishigori C; Nakagawa T; Hirano T; Yano I; Hirai M
    Biochem Biophys Res Commun; 2017 Apr; 485(2):227-233. PubMed ID: 28237700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
    Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
    [No Abstract]   [Full Text] [Related]  

  • 7. Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
    Zimmerman EI; Gibson AA; Hu S; Vasilyeva A; Orwick SJ; Du G; Mascara GP; Ong SS; Chen T; Vogel P; Inaba H; Maitland ML; Sparreboom A; Baker SD
    Cancer Res; 2016 Jan; 76(1):117-26. PubMed ID: 26677977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
    Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
    Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
    Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
    Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
    Li J; Gu J
    Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
    McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
    Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.
    Yeh CN; Chung WH; Su SC; Chen YY; Cheng CT; Lin YL; Chang WC; Chung-Yee Hui R; Chiang KC; Chen TW; Jan YY; Chen CW; Chen TJ; Yang CH; Hung SI
    J Invest Dermatol; 2014 Nov; 134(11):2768-2775. PubMed ID: 24802849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
    Manchen E; Robert C; Porta C
    J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
    Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.
    Yamamoto K; Shichiri H; Ishida T; Kaku K; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Yano I; Hirai M
    Biol Pharm Bull; 2017; 40(9):1530-1536. PubMed ID: 28867735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
    Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
    Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Jain L; Sissung TM; Danesi R; Kohn EC; Dahut WL; Kummar S; Venzon D; Liewehr D; English BC; Baum CE; Yarchoan R; Giaccone G; Venitz J; Price DK; Figg WD
    J Exp Clin Cancer Res; 2010 Jul; 29(1):95. PubMed ID: 20630084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
    Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
    Cancer Chemother Pharmacol; 2024 Jul; 94(1):57-66. PubMed ID: 38459188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.